Ximelagatran: light at the end of the tunnel or the next tunnel?
Sander
Gary E
GE
Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112-2825, USA.
Giles
Thomas D
TD
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D001596:Benzylamines; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran